NCT05935748
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05935748
Title Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors NiKang Therapeutics, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of California San Diego La Jolla California 92093 United States Details
Northwestern University - Feinberg School of Medicine Chicago Illinois 60611 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
University of Michigan-Rogel Cancer Center Ann Arbor Michigan 48109 United States Details
Nebraska Cancer Specialists Omaha Nebraska 68130 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065-6094 United States Details
UT Southwestern Medical Center Dallas Texas 75390-9324 United States Details
University of Virginia Health System Charlottesville Virginia 22908 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field